Reference

Alendronate reduces the risk of vertebral and clinical fractures in women with existing vertebral fractures: preliminary results of the Fracture Intervention Trial

Alendronate reduces the risk of vertebral and clinical fractures in women with existing vertebral fractures: preliminary results of the Fracture Intervention Trial. Black, D. M.; Cummings, S. R.; Karpf, D. B.; Cauley, J.; Ensrud, K.; Genant, H. K. 66376-36-1 is the cas registry number. This chemical is also mentioned in this article.; Haskell, W.; Marcus, R.; Nevitt, M. C.; Ott, S. M.; Quandt, S. A.; Torner, J. C.; Thompson, D. (Univ. California, San Francisco, CA 94105, USA). International Congress Series, 1118(Osteoporosis 1996), 315-319 (English) 1996 Elsevier. CODEN: EXMDA4. ISSN: 0531-5131. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The Fracture Intervention Trial (FIT) is a randomized study designed to test whether alendronate reduces risk in women aged 55-80 yr with low femoral neck BMD. FIT enrolled 6,459 women into two study arms. The Vertebral Fracture Arm, for which final results will be reported here, randomized 2,027 women with vertebral fractures to placebo (PBO) or 5 mg of alendronate (ALN); women with calcium intakes <1,000 mg/day received calcium/vitamin D supplements. Based on BMD results in other trials, the alendronate dose was increased to 10 mg/day at 2 yr with preservation of the double blind. Lateral spine X-rays were repeated after 2 and 3 yr, and new vertebral fractures (VFx, the primary endpoint) were defined by morphometry as a 320% (34 mm) decrease in at least 1 vertebral height. Nonspine clin. fractures were confirmed by X-ray reports. New symptomatic vertebral fractures were based on self-report and confirmed by X-rays. In Oct. 1995, the independent FIT Data Safety and Monitoring Board recommended early completion of the Vertebral Fracture Arm. As a result of this recommendation, which was based on issues of efficacy rather than safety, close out of the arm was scheduled to be completed in Feb., 1996. In this paper, we will present preliminary results for vertebral fractures, nonvertebral fractures, and safety. .

Pharmaceutical composition based on diphosphonates for the treatment of arthrosis

Pharmaceutical composition based on diphosphonates for the treatment of arthrosis. Rosini, Sergio; Fontanelli, Luciano (Instituto Gentili S.p.A., Italy). Eur. Pat. Appl. EP 203649 A2 3 Dec 1986, 10 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (European Patent Organization) CODEN: EPXXDW. CLASS: ICM: A61K031-66. APPLICATION: EP 86-200822 13 May 1986. 79778-41-9 and 66376-36-1 are cas registry numbers of chemicals which are used as reagents here. PRIORITY: IT 85-67478 24 May 1985. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 Diphosphonates XC(PO3H2)2(CH2)n(I; X = OH, Cl, F, H; Y = NH2, Cl, F, H; n = 1 - 5 with n 1 1 if Y = NH2) are useful for the treatment of arthrosis. A soln. for intraarticular use was formulated contg. Na clodronate 1000, 10% AcOH 2250, anhyd. NaOH 1520, glycine 15,000 mg and purified water to 1 L. Patients 65-80 yr old were treated with I at 10-100 mg, ~10% of the patients showed a striking improvement. .